06/09/2026
Learn about Clinical Trial DV-006, a study exploring disitamab vedotin (DV) for people diagnosed with HER2-positive, HER2-low, or HER2-ultralow, advanced or metastatic breast cancer.
DV is a targeted therapy designed to deliver treatment directly to cancer cells. This Phase1b/2 trial is evaluating safety, side effects, dosage and early signs of effectiveness.
This trial is shared for educational purposes only and may not be the right option for you; we encourage you to explore other clinical trials and discuss all possible options with your doctor.
Stay informed about ongoing clinical trials. For more on DV-OO6, check out all the posts in the series. Learn more at: https://bit.ly/3Q1uS6l